Literature DB >> 9774574

Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies.

C L Peyton1, M Schiffman, A T Lörincz, W C Hunt, I Mielzynska, C Bratti, S Eaton, A Hildesheim, L A Morera, A C Rodriguez, R Herrero, M E Sherman, C M Wheeler.   

Abstract

This study compared the performances of three human papillomavirus (HPV) detection tests with specimens collected by three alternative procedures. The HPV tests included the Hybrid Capture Tube test (HCT), the microplate-based Hybrid Capture II test (HC II), and the MY09-MY11 L1 consensus primer PCR-based assay. Initial cervical specimens were collected from study subjects with a broom device, and after Papanicolaou smears were made, residual specimens were placed into PreservCyt (PC), a liquid cytology medium. A second specimen was collected from each subject and placed into Digene Specimen Transport Medium (STM). The device for collection of the second specimen alternated with consecutive subjects between a conical cytology brush and a Dacron swab. At the 1.0-pg/ml cutoff, the results of the HC II agreed well with those of the PCR. Specifically, when PCR data were restricted to the types found by the HC II (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), there was greater than 90% agreement between the HC II and PCR results with both STM and PC. At a lower cutoff (0.2 pg/ml), HC II-positive results increased further, especially when the test was applied to the PC specimens. However, false-positive HC II results were more often observed at the 0.2-pg/ml cutoff. HC II yielded the highest HPV positivity with specimens placed into PC, followed by specimens collected with a conical brush and placed into STM and, last, by those collected with a Dacron swab and placed into STM. Our results demonstrate the utility of both the STM and PC specimen collection methods and show good agreement between the HC II and PCR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774574      PMCID: PMC105310     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project.

Authors:  R Herrero; M H Schiffman; C Bratti; A Hildesheim; I Balmaceda; M E Sherman; M Greenberg; F Cárdenas; V Gómez; K Helgesen; J Morales; M Hutchinson; L Mango; M Alfaro; N W Potischman; S Wacholder; C Swanson; L A Brinton
Journal:  Rev Panam Salud Publica       Date:  1997-05

2.  Analytic sensitivities of hybrid-capture, consensus and type-specific polymerase chain reactions for the detection of human papillomavirus type 16 DNA.

Authors:  S Cavuslu; C Mant; W G Starkey; J M Bible; C Biswas; B Kell; P Rice; J M Best; J Cason
Journal:  J Med Virol       Date:  1996-08       Impact factor: 2.327

3.  Identification of five novel human papillomavirus sequences in the New Mexico triethnic population.

Authors:  C L Peyton; C M Wheeler
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

4.  HPV testing in patients with low grade cervical cytological abnormalities: a follow up study.

Authors:  C S Herrington; M F Evans; F M Charnock; W Gray; J O'D McGee
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

5.  Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.

Authors:  P E Gravitt; C L Peyton; R J Apple; C M Wheeler
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection.

Authors:  A Schneider; D M Zahm; R Kirchmayr; V L Schneider
Journal:  Am J Obstet Gynecol       Date:  1996-05       Impact factor: 8.661

7.  Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing.

Authors:  M E Sherman; M H Schiffman; A T Lorincz; R Herrero; M L Hutchinson; C Bratti; D Zahniser; J Morales; A Hildesheim; K Helgesen; D Kelly; M Alfaro; F Mena; I Balmaceda; L Mango; M Greenberg
Journal:  Cancer       Date:  1997-04-25       Impact factor: 6.860

8.  Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance.

Authors:  J T Cox; A T Lorincz; M H Schiffman; M E Sherman; A Cullen; R J Kurman
Journal:  Am J Obstet Gynecol       Date:  1995-03       Impact factor: 8.661

9.  Intermethod variation in detection of human papillomavirus DNA in cervical smears.

Authors:  H L Smits; L J Bollen; S P Tjong-A-Hung; J Vonk; J Van Der Velden; F J Ten Kate; J A Kaan; B W Mol; J Ter Schegget
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

10.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

View more
  46 in total

1.  The Use of Molecular Techniques for the Diagnosis and Epidemiologic Study of Sexually Transmitted Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

2.  A novel strategy for human papillomavirus detection and genotyping with SybrGreen and molecular beacon polymerase chain reaction.

Authors:  K Szuhai; E Sandhaus; S M Kolkman-Uljee; M Lemaître; J C Truffert; R W Dirks; H J Tanke; G J Fleuren; E Schuuring; A K Raap
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.

Authors:  A Lytwyn; J W Sellors; J B Mahony; D Daya; W Chapman; N Ellis; P Roth; A T Lorincz; A Gafni
Journal:  CMAJ       Date:  2000-09-19       Impact factor: 8.262

4.  Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

5.  Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture.

Authors:  S D Vernon; E R Unger; D Williams
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

6.  Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.

Authors:  Maria T Sandri; Paola Lentati; Elvira Benini; Patrizia Dell'Orto; Laura Zorzino; Francesca M Carozzi; Patrick Maisonneuve; Rita Passerini; Michela Salvatici; Chiara Casadio; Sara Boveri; Mario Sideri
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 7.  Human papillomavirus infections in primary care.

Authors:  Folashade Ogunmodede; Steven H Yale; Bruce Krawisz; Gregory C Tyler; Anthony C Evans
Journal:  Clin Med Res       Date:  2007-12-17

8.  Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial.

Authors:  A Sargent; A Bailey; A Turner; M Almonte; C Gilham; H Baysson; J Peto; C Roberts; C Thomson; M Desai; J Mather; H Kitchener
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

9.  Can clinical tests help monitor human papillomavirus vaccine impact?

Authors:  Elissa Meites; Carol Lin; Elizabeth R Unger; Martin Steinau; Sonya Patel; Lauri E Markowitz; Susan Hariri
Journal:  Int J Cancer       Date:  2013-03-13       Impact factor: 7.396

10.  The laboratory diagnosis of genital human papillomavirus infections.

Authors:  François Coutlée; Danielle Rouleau; Alex Ferenczy; Eduardo Franco
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-03       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.